Attentional Bias Modification in Patients With Posttraumatic Stress Disorder

Posttraumatic Stress Disorder Clinical Trial

Official title:

Effects of Attentional Bias Modification on Attentional Bias and Symptoms of Posttraumatic Stress Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00764101
• Other study ID #: 60-60105-98-128
• Status: Completed
• Phase: Phase 2
• First received: September 29, 2008
• Last updated: July 7, 2011
• Start date: September 2008
• Est. completion date: April 2010

Study information

• Verified date: July 2011
• Source: PsyQ
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)
• Study type: Interventional

Clinical Trial Summary

Randomized, placebo-controlled trial of 9 sessions of computerized attentional bias training on attentional bias and on symptoms of Posttraumatic Stress Disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of Posttraumatic Stress Disorder

Exclusion Criteria:

• Diagnosis of psychosis, drug- or alcohol dependency/abuse;

• Unable to fill in questionnaires in Dutch;

• Color blindness (Stroop test).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Posttraumatic Stress Disorder
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Behavioral:
• Attentional Bias Modification
computerized training to reduce attentional bias in posttraumatic stress disorder

Locations

Country	Name	City	State
Netherlands	PsyQ Haaglanden, department of psychotrauma	Den Haag	Zuid Holland

Sponsors (3)

Lead Sponsor	Collaborator
PsyQ	Leiden University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinician-Administered PTSD Scale (CAPS)		End of Trial + 3 week Follow-Up	No
Secondary	PTSD symptoms (self-report)		end of trial + 3wk Follow Up	No
Secondary	Attentional Bias (dot-probe test)		End of trial + 3wk Follow-up	No
Secondary	Emotional Stroop Interference		End of trial + 3wk Follow Up	No